Skip to main content
MedPathMedPath Home
Clinical Trials/TCTR20221113004
TCTR20221113004
Completed
Not Applicable

The Real-world Clinical Outcomes of Favipiravir Treatment in Mild to Moderate COVID-19 Patients in Single Outpatient Visit Followed by Home Isolation: a Multicenter, case-control Study

Chulabhorn Royal Academy0 sites1,037 target enrollmentNovember 13, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Not specified
Sponsor
Chulabhorn Royal Academy
Enrollment
1037
Status
Completed
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 13, 2022
End Date
May 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •1\.Confirmed SARS\-COV\-2 infected cases by Reverse Transcriptase\-Polymerase Chain Reaction or Rapid antigen testing from respiratory specimens which were treated with outpatients, home isolation, or lived in quarantine facilities
  • •2\.Mild to moderate illness
  • •3\.Participants accept informed consent

Exclusion Criteria

  • •1\.Age less than 20\-year\-old
  • •2\.Who lives in long\-term facilities, or prison
  • •3\. Patients who need hospitalization on the initial day
  • •3\.Severe or critical COVID\-19
  • •3\.1respiratory rate \> 30 / min
  • •3\.2SpO2 less than 95%
  • •3\.3Patients who need oxygen therapy
  • •3\.4Respiratory failure
  • •3\.5Shock or BP\<90/60
  • •3\.6Multi\-organ failure

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Phase 3
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1
IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
Completed
Phase 3
Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)covid positive.Coronavirus infection, unspecifiedB34.2
IRCT20150107020592N26Masih Daneshvari Hospital20
Recruiting
Phase 3
The therapeutic effect of Favipiravir in COVID-19 patients
IRCT20211004052664N1Shahid Beheshti University of Medical Sciences80
Recruiting
Phase 3
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19
IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
Completed
Phase 3
Phase III Clinical Study on Favipiravir in Patients with Severe Fever with Thrombocytopenia SyndromeSevere Fever with Thrombocytopenia Syndrome (SFTS)
JPRN-jRCT2080223816FUJIFILM Toyama Chemical Co., Ltd. (Former Toyama Chemical Co., Ltd.)30